The latest announcement is out from NLS Pharmaceutics ( (NLSP) ).
On January 16, 2025, NLS Pharmaceutics announced that Kadimastem has called for a special general meeting to approve their merger, a crucial step facilitated by the Central District Court in Israel allowing a reduced timeframe for the process. This move follows NLS’s successful fundraising endeavors, including a $500,000 closing and a $3.2 million investment, aimed at creating a strong Nasdaq-listed biotechnology firm with a diverse therapy pipeline, potentially redefining the industry landscape and enhancing stakeholder value.
More about NLS Pharmaceutics
NLS Pharmaceutics Ltd. is a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for rare and complex central nervous system disorders. It collaborates with world-class partners and scientists to address unmet medical needs. Founded in 2015 and based in Zurich, the company is driven by a seasoned management team experienced in product development and commercialization.
YTD Price Performance: -8.26%
Average Trading Volume: 1,060,393
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $5.02M
See more data about NLSP stock on TipRanks’ Stock Analysis page.